New Delhi to host 7th edition of ‘India Pharma & India Medical Device’ on April 25-27

New Delhi: To meet the critical requirements of the country, India’s dependency on import for pharma and medical devices must be reduced, says Dr Mansukh Mandaviya, Union Minister for Chemicals & Fertilizers, and Health & Family Welfare.

Addressing the Curtain Raiser press conference on the 7th edition of India Pharma & Indian Medical Device 2022 organized by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, and the Federation of Indian Chambers of Commerce and Industry (FICCI), Dr Mandaviya said that the domestic manufacturing needs to scale up as we want to dominate the world and our aim is not to be dependent on anyone.

He added that currently India has highest manufacturing capacity for generic medicines. He further said that in order to increase the production of patented drugs manufacturing in India, both innovation and research is required. To bring more innovation and research, the government is taking various steps and soon the government will announce a policy also in this regard, noted Dr Mandaviya.

He further added that this conference will decide the roadmap of Indian Pharma and Indian Medical devices sector for the next 25 years to take India beyond ‘Pharmacy of the World’.

Bhagwanth Khuba, Minister of State, Ministry of Chemicals & Fertilizers, said that with the growth in pharmaceutical sector, India is aspiring to become a pharmaceutical hub. He further stated that to boost the Indian medical devices sector we need to bring new technologies, innovation along with focus on R&D activities. We have to increase the production of Indian medical devices to reduce the import dependency, he added.

S. Aparna, Secretary, Department of Pharmaceuticals, said that Indian Pharmaceutical & Medical Device Sector requires collaboration between industries, academia, researchers, regulators & policymakers that’ll help these two sectors. The government has formulated several mechanisms including empowered group of secretaries, project development cell, PLI schemes, & a conducive policy environment to strengthen the pharma & medical device ecosystems.